Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697541 · ClinicalTrials.gov registry record · Phase 2
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00697541 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 20 participants.
The verdict
NCT00697541, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
Interventions
- DRUG 0.18% COL-118 facial gel (1.8 mg brimonidine)
- DRUG 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
- DRUG Advanced Eye Relief
- DRUG COL-118 facial gel vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697541
The ClinicalTrials.gov registry entry for NCT00697541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 0.18% COL-118 facial gel (1.8 mg brimonidine) is the first listed.
NCT00697541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697541 about?
NCT00697541 is a clinical study titled "Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%". Phase II systemic bioavailability crossover study to measure the exposure of Col-118 topical 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2%
What is the current status of trial NCT00697541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00697541?
The interventions under investigation include: 0.18% COL-118 facial gel (1.8 mg brimonidine) (DRUG), 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) (DRUG), Advanced Eye Relief (DRUG), COL-118 facial gel vehicle (DRUG).
Who is sponsoring clinical trial NCT00697541?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.